sermorelin+injection: Frequently asked questions

Consider peptide purity and excipient profile. Low-purity sermorelin or solutions with excessive excipients increase tissue irritation independent of injection technique. Research-grade peptides synthesised under USP standards with minimal excipient load. Like those in Real Peptides' research portfolio. Produce measurably less injection site discomfort than lower-purity alternatives.

Repeated injection at the same site within 48–72 hours causes localized tissue inflammation and fibrosis that impair subsequent absorption. Maintain minimum 1-inch spacing between injection points within the same anatomical region, or alternate between abdomen and thigh if daily administration is required. Injection site rotation prevents lipohypertrophy (fatty tissue buildup) that reduces peptide bioavailability by 15–25% in affected areas.

Intramuscular sermorelin administration produces higher peak plasma concentrations (30–40% increase) and shorter duration compared to subcutaneous dosing due to greater muscle tissue vascularity. If research protocol requires subcutaneous kinetics, the dose must be excluded from pharmacokinetic analysis. Prevent recurrence by reducing needle insertion depth to 6mm maximum and ensuring adequate subcutaneous tissue pinch before injection.

Stop the injection, withdraw the needle, and wait 2–3 minutes before attempting a different site. Intense stinging during injection usually means intradermal placement (too shallow) or injection into a site with residual inflammation. Verify needle depth. 8 mm needles should penetrate at 90 degrees in patients with adequate subcutaneous fat.

Apply cold compression for 10 minutes immediately after noticing the lump, then switch to warm compression 24 hours later to accelerate resorption. A firm subcutaneous nodule lasting 3–5 days post-injection indicates localised sterile inflammation from too-rapid delivery or repeated trauma to the same site. Avoid injecting that site for at least 10 days and ensure you're rotating through a full 12-zone field.

Discard the vial immediately. Do not attempt filtration or clarification. Particulate matter indicates peptide aggregation, microbial contamination, or glass particulates from vial breakage. Administering contaminated solution introduces foreign protein aggregates or endotoxins that trigger immune responses and invalidate research data. Sermorelin should reconstitute to a clear, colorless solution within 60 seconds of adding bacteriostatic water.

Patients with low body fat (<12% for men, <20% for women) may lack sufficient abdominal adipose tissue for comfortable subcutaneous injection. In this case, expand your rotation to include the outer thigh (vastus lateralis region, mid-thigh level) as a fifth and sixth zone. Thigh injections produce slightly lower peak plasma concentrations but remain clinically effective. Alternatively, the back of the upper arm (triceps region) can serve as additional rotation zones, though this site requires assistance or flexibility to self-administer. Never inject into areas with <1 cm of pinchable subcutaneous fat. Insufficient tissue depth risks intramuscular injection, which alters absorption kinetics unpredictably.

Stop injecting into that quadrant immediately and avoid the area entirely for 12–16 weeks. The lump represents established lipohypertrophy. Continued injection into or near that tissue will worsen the nodule and further reduce absorption. Shift your rotation to the three remaining quadrants, maintaining one-inch spacing within each. Most lipohypertrophic nodules resolve spontaneously over 3–6 months once the mechanical stimulus is removed, though larger nodules (>1 cm diameter) may persist longer or require manual massage to break up fibrous tissue.

Do not guess. Injecting into a site used within the past 72 hours significantly increases lipohypertrophy risk. If you cannot definitively recall your last injection point, choose a site in a different anatomical quadrant entirely. Err toward over-rotation rather than under-rotation. Going forward, implement a tracking system: photograph your abdomen after each injection with a small adhesive dot marking the site, or use a written log with date, time, and quadrant recorded. Tracking eliminates this problem entirely.